{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:08:47Z","timestamp":1788322127646,"version":"build-2803163510"},"reference-count":43,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Ampicillin resistant and glycopeptide susceptible Enterococcus faecium bloodstream infection (GSEF-BSI) incidence has risen. However, the treatment of choice remains unknown. Daptomycin use for the treatment of enterococcal infections has increased, despite effectiveness and safety concerns. The objective was to compare the effectiveness and safety of daptomycin and glycopeptides in the treatment of GSEF-BSI. Methods: This was a single-centre, retrospective observational cohort study performed at Hospital del Mar (Barcelona, Spain), from January 2006\u2013May 2018. The primary outcome was clinical cure at the end of the therapy, and secondary outcomes included 14-day, 30-day, in-hospital mortality, and length of stay. Results: From a total of 192 patients with GSEF-BSI, 54 (28.1%) were treated with glycopeptides and 17 (8.9%) with daptomycin. Patients treated with daptomycin presented a lower clinical cure than patients treated with glycopeptides (58.8% vs. 83.3%, RR 0.416 (95% CI 0.189\u20130.915)). After controlling for confounding variables by means of multivariate analysis the significative difference was confirmed (aOR 4.313, 95% CI, 1.053\u201317.660). The need for treatment discontinuation due to adverse events was similar. Conclusions: Patients with GSEF-BSI treated with glycopeptides showed a higher clinical cure than those treated with daptomycin.<\/jats:p>","DOI":"10.3390\/antibiotics10060716","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T10:30:25Z","timestamp":1623666625000},"page":"716","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia: A Cohort Study"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4975-8798","authenticated-orcid":false,"given":"Daniel","family":"Echeverr\u00eda-Esnal","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital del Mar, Passeig Maritim 25\u201329, 08003 Barcelona, Spain"},{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Dr. Aiguader 88, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Sorli","sequence":"additional","affiliation":[{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Dr. Aiguader 88, 08003 Barcelona, Spain"},{"name":"Infectious Diseases Department, Hospital del Mar, Passeig Maritim 25\u201329, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Prim","sequence":"additional","affiliation":[{"name":"Microbiology Department, Laboratori de Refer\u00e8ncia de Catalunya, Carrer de la Selva 10, 08820 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Martin-Ontiyuelo","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital del Mar, Passeig Mar\u00edtim 25, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-5459","authenticated-orcid":false,"given":"Juan Pablo","family":"Horcajada","sequence":"additional","affiliation":[{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Dr. Aiguader 88, 08003 Barcelona, Spain"},{"name":"Infectious Diseases Department, Hospital del Mar, Passeig Maritim 25\u201329, 08003 Barcelona, Spain"},{"name":"Department of Medicine, CEXS-Universitat Pompeu Fabra, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-1836","authenticated-orcid":false,"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital del Mar, Passeig Maritim 25\u201329, 08003 Barcelona, Spain"},{"name":"Department of Pharmacology, Universitat Aut\u00f2noma de Barcelona, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e00058-18","DOI":"10.1128\/CMR.00058-18","article-title":"The enterococcus: A model of adaptability to its environment","volume":"32","author":"Rice","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/ijcp.12754","article-title":"Enterococcal bloodstream infection. Design and validation of a mortality prediction rule","volume":"70","author":"Landecho","year":"2016","journal-title":"Int. J. Clin. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/1469-0691.12028","article-title":"The changing epidemiology of bacteraemias in Europe: Trends from the European antimicrobial resistance surveillance system","volume":"19","author":"Jarlier","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1017\/S0950268818002479","article-title":"Enterococcal bacteraemia: Predictive and prognostic risk factors for ampicillin resistance","volume":"146","author":"Matsumura","year":"2018","journal-title":"Epidemiol. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jac\/dkn360","article-title":"Emergence of ampicillin-resistant Enterococcus faecium in Danish hospitals","volume":"62","author":"Lester","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ijantimicag.2019.08.018","article-title":"Linezolid vs. glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: A propensity score matched comparative study","volume":"54","author":"Sorli","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/cid\/civ444","article-title":"Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients","volume":"61","author":"Britt","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrmicro2761","article-title":"The rise of the Enterococcus: Beyond vancomycin resistance","volume":"10","author":"Arias","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_9","unstructured":"European Centre for Disease Prevention and Control (2021, May 28). Data from ECDC Surveillance Atlas\u2014Antimicrobial Resistance, Available online: https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx?Dataset=27&HealthTopic=4."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1080\/14656566.2019.1675637","article-title":"Important new therapies for methicillin-resistant Staphylococcus aureus","volume":"20","author":"Bassetti","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1086\/519470","article-title":"Limitations of Vancomycin in the Management of Resistant Staphylococcal Infections","volume":"45","author":"Kollef","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkx349","article-title":"Daptomycin","volume":"73","author":"Heidary","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01289-13","article-title":"Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia","volume":"58","author":"Balli","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.cmi.2020.04.027","article-title":"Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: A EUCAST position paper","volume":"26","author":"Turnidge","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1060028014556879","article-title":"Vancomycin-Resistant Enterococcal Bacteremia Pharmacotherapy","volume":"49","author":"Patel","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","unstructured":"(2021, May 06). Eucast Clinical Breakpoints. Available online: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_11.0_Breakpoint_Tables.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/cid\/ciy749","article-title":"Pharmacodynamic Analysis of Daptomycin-Treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint","volume":"68","author":"Avery","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","first-page":"1240","article-title":"Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute","volume":"70","author":"Satlin","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00134-019-05875-9","article-title":"Understanding resistance in enterococcal infections","volume":"46","author":"Rello","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/cid\/ciw173","article-title":"Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated with Daptomycin: Is it Time to Change the Breakpoint?","volume":"62","author":"Shukla","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1177\/1060028020971216","article-title":"A Pharmacokinetic-Pharmacodynamic Analysis to Dose Optimize Daptomycin in Vancomycin-Resistant Enterococcus faecium: Is the Answer Fixed Dosing or Lowering Breakpoints?","volume":"55","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Santimaleeworagun, W., Changpradub, D., Thunyaharn, S., and Hemapanpairoa, J. (2019). Optimizing the dosing regimens of daptomycin based on the susceptible dose-dependent breakpoint against vancomycin-resistant enterococci infection. Antibiotics, 8.","DOI":"10.3390\/antibiotics8040245"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: Data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e00600-19","DOI":"10.1128\/JCM.00600-19","article-title":"The New, New Daptomycin Breakpoint for Enterococcus spp.","volume":"57","author":"Humphries","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"890.e1","DOI":"10.1016\/j.cmi.2016.07.018","article-title":"Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: Implications of daptomycin dose","volume":"22","author":"Chuang","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e00315-18","DOI":"10.1128\/AAC.00315-18","article-title":"Influence of inoculum effect on the efficacy of daptomycin monotherapy and in combination with -lactams against daptomycin-susceptible enterococcus faecium harboring liasr substitutions","volume":"62","author":"Kebriaei","year":"2018","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02074-19","article-title":"Impact of daptomycin dose exposure alone or in combination with \u03b2-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model","volume":"64","author":"Jahanbakhsh","year":"2020","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/infdis\/jiaa319","article-title":"Mechanistic Insights into the Differential Efficacy of Daptomycin plus \u03b2-Lactam Combinations against Daptomycin-Resistant Enterococcus faecium","volume":"222","author":"Kebriaei","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofv156","article-title":"Prolonged use of oritavancin for vancomycin-resistant enterococcus faecium prosthetic valve endocarditis","volume":"2","author":"Johnson","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14656566.2018.1479397","article-title":"Combatting resistant enterococcal infections: A pharmacotherapy review","volume":"19","author":"Mercuro","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1128\/AAC.02622-18","article-title":"Treatment of multidrug-resistant vancomycin-resistant enterococcus faecium hardware-associated vertebral osteomyelitis with oritavancin plus ampicillin","volume":"63","author":"Dahesh","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cardoso, T., Almeida, M., Friedman, N.D., Arag\u00e3o, I., Costa-Pereira, A., Sarmento, A.E., and Azevedo, L. (2014). Classification of healthcare-associated infection: A systematic review 10 years after the first proposal. BMC Med., 12.","DOI":"10.1186\/1741-7015-12-40"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-140-1-200401060-00008","article-title":"International prospective study of Klebsiella pneumoniae bacteremia: Implications of extended-spectrum beta-lactamase production in nosocomial Infections","volume":"140","author":"Paterson","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"ref_39","unstructured":"(2021, May 06). Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-Central Line Associated Bloodstream Infection), Available online: https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/4psc_clabscurrent.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1086\/318717","article-title":"Attributable Mortality Rate and Duration of Hospital Stay Associated with Enterococcal Bacteremia","volume":"32","author":"Becerril","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/cid\/cit223","article-title":"Effect of adequate single-drug vs combination antimicrobial therapy on mortality in pseudomonas aeruginosa bloodstream infections: A post hoc analysis of a prospective cohort","volume":"57","author":"Suarez","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.2215\/CJN.02070606","article-title":"Defining acute renal failure: RIFLE and beyond","volume":"1","author":"Vanholder","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.eimc.2009.06.011","article-title":"Caracter\u00edsticas cl\u00ednicas diferenciales entre las bacteriemias por Enterococcus faecalis y Enterococcus faecium","volume":"28","author":"Sorli","year":"2010","journal-title":"Enferm. Infecc. Microbiol. Clin."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/6\/716\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:14:09Z","timestamp":1760163249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/6\/716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["antibiotics10060716"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10060716","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]}}}